Meet our UK Innovators attending this event
Delivering a breakthrough unsupervised AI to extract clinical features from doctors notes.
Visit company site
Dr Vibhor Gupta
Director & Founder
At BIO International Convention 2023, Pangaea are looking to connect with:
biopharmaceutical companies, synthetic biology companies and investors.
Maximising value through the integrated application of Pharmaceutical Development and Clinical Pharmacology expertise.
Visit company site
Paul Stott
CEO
At BIO International Convention 2023, Seda are looking to connect with:
pharmaceutical companies, consumer health companies and investors.
Axol Bioscience generates cells derived from human induced pluripotent stem cells (hiPSC) for more reliable, more robust, human models of disease.
Visit company site
Liam Taylor
CEO
At BIO International Convention 2023, Axol Bioscience are looking to connect with:
medtech manufacturers and investors.
Epitopea are looking to generate therapeutic off-the-shelf cancer vaccines repurposing the mRNA technology that came to prominence in the COVID pandemic, using a new class of tumour-specific antigens.
Visit company site
Dr Jon Moore
CEO
At BIO International Convention 2023, Epitopea are looking to connect with:
diagnostic companies, hospitals and healthcare providers and investors.
Offering a flexible manufacturing platform that closes, automates and standardizes cell and gene therapy manufacturing.
Visit company site
Jason Foster
CEO
At BIO International Convention 2023, Ori Biotech are looking to connect with:
hospitals and healthcare providers, patient organisations and investors.
Developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in type 1 diabetes.
Visit company site
Nara Daubeney
COO & Co-Founder
At BIO International Convention 2023, Phaim Pharma are looking to connect with:
pharmaceutical companies and investors.
Aptamer Group develops next-generation oligonucleotide binders using its proprietary Optimer® platform which consists of three parallel processes optimized for target type (small molecules, proteins and cells).
Visit company site
Arron Tolley
CEO
At BIO International Convention 2023, Aptamer Group are looking to connect with:
hospitals and healthcare providers, patient organisations and investors.
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics based on a unique, patent protected, discovery platform.
Visit company site
Theodora Harold
CEO
At BIO International Convention 2023, Crescendo Biologics are looking to connect with:
pharmaceutical companies and investors.
Elasmogen develops innovative antibody-like drugs called soloMERs for the treatment of autoimmune inflammatory diseases and cancer.
Visit company site
Dr Caroline Barelle
CEO
At BIO International Convention 2023, Elasmogen are looking to connect with:
hospitals and healthcare providers, patient organisations and investors.
Novel multi-omics liquid biopsy tests via Extracellular Vesicles (EVs) enabling the real time analysis of tissue-specific bioactivity in blood. Its first product is a blood test for early detection of liver cancer among high-risk patients.
Visit company site
Pierre Arsene
Founder & CEO
At BIO International Convention 2023, Mursla are looking to connect with:
pharmaceutical companies and investors.
Providing services to clients for the discovery of Antibody/ Autoantibody Biomarker Signatures.
Visit company site
Adam M Hill
CEO
At BIO International Convention 2023, Oncimmune are looking to connect with:
hospitals and healthcare providers, patient organisations and investors.
Using an innovative platform technology called PODS, Cell Guidance Systems can stabilize and sustainably release proteins for a variety of applications.
Visit company site
Michael Jones
Founder & CEO
At BIO International Convention 2023, Cell Guidance Systems are looking to connect with:
pharmaceutical companies and investors.
